Sharon Barr

EVP, BioPharmaceuticals R&D · AstraZeneca

Pharmaceuticals

Sharon Barr leads BioPharmaceuticals research and development at AstraZeneca. Her scientific leadership includes rare-disease research, translational medicine, biomarkers and product development at Alexion.

Last reviewed: Nov 16, 2026

Executive Summary

Sharon Barr leads BioPharmaceuticals research and development at AstraZeneca. Her scientific leadership includes rare-disease research, translational medicine, biomarkers and product development at Alexion.

Career Highlights

  • Joined AstraZeneca’s Senior Executive Team on August 1, 2023.
  • Moved from Alexion’s research and product-development leadership.
  • Completed molecular-biology doctoral work and postdoctoral research on DNA damage and repair.

Professional Journey

Barr earned a Ph.D. in molecular biology at New York University and undertook postdoctoral work at Stanford, where her research focused on DNA damage and repair. Her subsequent industry work covered translational research, precision medicines and global development.

She joined Alexion in 2013 and later served as senior vice president and head of Research and Product Development. Her remit included drug discovery, process development, clinical supply, biomarkers, bioanalytical discovery, rare-disease diagnostics and bioinformatics.

Her Alexion responsibilities extended from identifying research targets through development and post-marketing work. In August 2023 she joined AstraZeneca’s Senior Executive Team as executive vice president for BioPharmaceuticals R&D, succeeding Mene Pangalos.

In the group role, Barr leads discovery through late-stage development for cardiovascular, renal and metabolic medicines and respiratory and immunology programs. The Healthcare Businesswomen’s Association recognized her as a Luminary in 2022.

Education

Ph.D. — New York University — Molecular Biology.